ArticleMolecular and clinical oncology2014
Expression and clinical significance of girdin in gastric cancer.
Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Girdin acts as an oncogene in gastric cancer by regulating AKT/GSK3β/β-catenin signaling.Functional & integrative genomics · 2023Article
- Girdin knockdown promotes apoptosis in colorectal cancer via miR-29c-3p/Girdin axis.Translational cancer research · 2019Article
- Review
- Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- GIV/Girdin (Gα-interacting, Vesicle-associated Protein/Girdin) Creates a Positive Feedback Loop That Potentiates Outside-in Integrin Signaling in Cancer Cells.The Journal of biological chemistry · 2016Article
- The untapped potential of tyrosine-based G protein signaling.Pharmacological research · 2016Review
- miR-101 Inhibiting Cell Proliferation, Migration and Invasion in Hepatocellular Carcinoma through Downregulating Girdin.Molecules and cells · 2016Article
- Integrins activate trimeric G proteins via the nonreceptor protein GIV/Girdin.The Journal of cell biology · 2015Article
- Review
- Multimodular biosensors reveal a novel platform for activation of G proteins by growth factor receptors.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the most common malignant tumors and the second leading cause of cancer-related mortality. Elucidating the molecular mechanism underlying the development of gastric cancer is crucial in identifying gastric cancer-susceptible populations, screening for tumor markers and in the application of gene therapy. This study was conducted to investigate girdin expression in gastric cancer and para-cancer tissues and to elucidate the role of girdin in the development of gastric cancer. Tissue micro-array and streptavidin-peroxidase immunohistochemical staining were used to detect girdin expression in 105 gastric cancer and 72 para-cancer tissue samples. Analyses of the patients' clinical and pathological data were also performed. The expression ratio of girdin was 40.0% in gastric cancer and 11.1% in the para-cancer tissues and the difference was statistically significant (P<0.05). Girdin expression was found to be positively correlated (P<0.05) with tumor invasion depth and lymph node metastasis, while no significant associations were found between girdin expression and gender, age, tumor size, pathological grade and clinical stage (P>0.05). In conclusion, the upregulation of girdin expression in gastric cancer may contribute to tumor metastasis and cancer development, suggesting that girdin may be a novel indicator for evaluating lymph node metastasis and gastric cancer outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.